Dr. Reddy's Laboratories has released generic versions of medications for treating Alzheimer's disease, depression and breast cancer in the United States.


Dr. Reddy's Laboratories, generic versions, donepezil hydrochloride tablets, Aricept, venlafaxine hydrochloride extended-release capsules, Effexor XR, letrozole tablets, Femara, bioequivalent generic version, Eisai, Wyeth, Novartis, pharmaceutical, Food and Drug Administration, FDA, Alzheimer's disease, depression, breast cancer




































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Dr. Reddy's ships three new generics in U.S.

June 6th, 2011

HYDERABAD, India – Dr. Reddy's Laboratories has released generic versions of medications for treating Alzheimer's disease, depression and breast cancer in the United States.

The India-based pharmaceutical maker said Monday that it has rolled out donepezil hydrochloride tablets in 5-mg and 10-mg strengths), available in 30-, 90- and 500-count bottles.

According to the company, the product is a bioequivalent generic version of Eisai's Aricept tablets, which are used to treat dementia stemming from Alzheimer's disease.

Dr. Reddy's also has shipped venlafaxine hydrochloride extended-release capsules in dosages of 37.5 mg, 75 mg and 150 mg strengths. Also available in available in 30-, 90- and 500-count bottles, the medication is a bioequivalent generic version of Wyeth's Effexor XR extended-release capsules for treating major depressive disorder, anxiety and panic disorder.

In addition, Dr. Reddy's has launched letrozole tablets 2.5 mg in 30-count bottles. The company said the product is a bioequivalent generic of Novartis' Femara, a treatment for breast cancer in postmenopausal women.

According to IMS Health data cited by Dr. Reddy's, Aricept brand and donepezil hydrochloride generic tablets had combined U.S. sales of about $2.3 billion for the 12 months ended March 31. Also during that time span, Effexor XR brand and venlafaxine extended-release generic capsules had total U.S. sales of $2.3 billion, and Femara brand tablets had U.S. sales of $702 million.

The Food and Drug Administration approved Dr. Reddy's abbreviated new drug applications (ANDAs) for donepezil hydrochloride tablets and venlafaxine hydrochloride extended-release capsules in May, while the company's ANDA for letrozole tablets was approved last week.

Advertisement